ASX:PCK PainChek (PCK) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free PCK Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PainChek alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About PainChek Stock (ASX:PCK)PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia and internationally. The company offers PainChek, which uses camera in smartphones and tablets for facial scan that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia and pre-verbal infants. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. PCK Stock News HeadlinesMarch 21, 2024 | finance.yahoo.comPainChek leads innovation in AI-based pain assessmentNovember 15, 2023 | finance.yahoo.comShareholders May Not Be So Generous With PainChek Limited's (ASX:PCK) CEO Compensation And Here's WhyApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 4, 2023 | health.usnews.comNeena PackOctober 10, 2023 | msn.comClosing Bell: War – Gold – Oil – The ASX – MondayOctober 9, 2023 | nz.finance.yahoo.comTaylor Swift's Old 'Soccer Mom' Impression Goes Viral Amid Travis Kelce FrenzyOctober 9, 2023 | finance.yahoo.comInvestors ignore increasing losses at PainChek (ASX:PCK) as stock jumps 37% this past weekSeptember 21, 2023 | fool.com.auWhy did this ASX biotech stock explode 36% today?April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.September 12, 2023 | afr.comHealthtech PainChek seeks equity injectionAugust 6, 2023 | appleinsider.comMagSafe Battery PackApril 13, 2023 | travel.usnews.com35 Essentials for Your 2023 CruiseApril 9, 2023 | bbc.co.ukSainsbury's defends vac-pack mince after complaintsMarch 23, 2023 | finance.yahoo.comPainChek Limited (PCK.AX)January 16, 2023 | nz.finance.yahoo.comWe're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn RateOctober 1, 2022 | reuters.comPCK.AX - PainChek Ltd | Stock Price & Latest News | ReutersAugust 9, 2022 | finance.yahoo.comIs PainChek (ASX:PCK) In A Good Position To Invest In Growth?March 3, 2022 | finance.yahoo.comWe Think PainChek (ASX:PCK) Can Afford To Drive Business GrowthJanuary 15, 2022 | msn.comWeekly Small Cap and IPO Wrap: Like Mentos to CokeDecember 3, 2021 | finance.yahoo.comWhen Will PainChek Limited (ASX:PCK) Become Profitable?December 1, 2021 | msn.comOsinbajo lauds Okowa, inaugurates Delta IPPDecember 1, 2021 | msn.comAtaga’s murder: Witness absence stalls Chidinma’s trialDecember 1, 2021 | msn.comNo agreement on severance package with NFF – RohrDecember 1, 2021 | msn.comFoundation moves to enhance safety of women, youthsNovember 29, 2021 | msn.comWhat the heck is going on with the PainChek (ASX:PCK) share price?September 5, 2021 | news.yahoo.comBail set at $10 million cash for Eric Reinbold, the Oklee man accused of murdering his wifeJuly 23, 2021 | au.finance.yahoo.comTotal Brain Limited (TTB.AX)See More Headlines Receive PCK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainChek and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolASX:PCK CUSIPN/A CIKN/A Webwww.painchek.com Phone1800 098 809FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-261.23% Return on Assets-97.22% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio3.60 Sales & Book Value Annual Sales$2.48 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,640,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.37 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Philip Daffas B.Sc.Dip EENG, GAICD, M.B.A., MD, CEO & DirectorMr. Iain McAdamChief Financial OfficerMr. Andrew HogganManager & Head of OperationsMr. Scott Robertson M.B.A.Chief Technology OfficerProf. Jeff Hughes Ph.D.Chief Scientific OfficerMr. David AllsoppHead of Business DevelopmentMs. Natalie ClimoCompany SecretaryMore ExecutivesKey Competitors1st GroupASX:1STAclarionNASDAQ:ACONWAlcidion GroupASX:ALCArcturis DataOTCMKTS:SSYNFArtryaASX:AYAView All CompetitorsInsidersJohn MurraySold 397,931 sharesTotal: $9,948.28 ($0.03/share)Ross HarricksSold 477,327 sharesTotal: $20,047.73 ($0.04/share)Cynthia PayneBought 675,676 shares on 9/27/2023Total: $20,270.28 ($0.03/share) This page (ASX:PCK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainChek Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
